Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma

Journal of Clinical Pathology

Volumn 50, Issue 3, 1997, Pages 212-217

  González, María Victoria ^a   Artímez, Manuel L ^a   Rodrigo, Luis ^a   López Larrea, Carlos ^a   Menéndez, María J ^a   Alvarez, Victoria ^a   Pérez, Ramón ^a   Fresno, Manuel F ^a   Pérez, María J ^a   Sampedro, Andrés ^a   Coto, Eliecer ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Barrett's oesophagus; Loss of heterozygosity; Single strand conformation polymorphism; Tumour suppressor genes

Indexed keywords

PROTEIN P16; PROTEIN P53;

ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; DYSPLASIA; ESOPHAGUS CARCINOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 8044233038     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.3.212     Document Type: Article

References (38)

1. Phillips RW, Wong RKH. Barrett's esophagus: natural history, incidence, etiology and complications. Gastroenterol Clin North Am 1991;20:791-816.
2. Miller BA, Ries LAG, Hankey BF, Kosary CL, Edwards BK. Cancer statistics review, 1973-1989. NIH Publication No 92-2789. Bethesda MD: US Department of Health and Human Services.
3. Levine DS, Reid BJ, Endoscopic diagnosis of esophageal neoplasms. In: Sivak M, ed. Gastrointestinal endoscopy clinics of North America. Philadelphia: WB Saunders, 1992:395-413.
4. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high grade dyplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
5. Rusch VW, Levine DS, Haggitt RC, Reid BJ. The management of high grade dysplasia and early cancer in Barrett's esophagus. Cancer 1994;74:1225-9.
6. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, Van Deventer G, Denbesten L, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognisable neoplastic lesions. Gastroenterology 1988;94:81-90.
7. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al. 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991:51:5482-6.
8. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54:2292-5.
9. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
10. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106: 1589-95.
11. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993;53:1889-94.
12. Greenwald BD, Huang Y, Baum R, Meltzer SJ. Barrett's carcinoma in a 25 year old man with point mutation of the p53 tumor suppressor gene. Int J Oncol 1992;1:271-5.
13. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fékété F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-8.
14. McKinley MJ, Budman DR, Grueneberg D, Bronzo RL, Wissman GS, Kahn E. DNA content in Barrett's esophagus and esophageal malignancy. Am J Gastroenterol 1987;82:1012-5.
15. Reid BJ, Blount PL, Robin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992; 102:1212-9.
16. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 1988;60:65-71.
17. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
18. Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, et al. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 1992;52:6525-30.
19. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 1993; 90:3221-5.
20. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle-regulator potentially involved in the genesis of many tumor types. Science 1994; 264:436-40.
21. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang H-Y, Rhyu M-G, et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994;54:6094-6.
22. Serrano M, Hannon G, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 1994;366:704-7.
23. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutations of the MTS1/CDK4I (multiple tumor suppressor 1/ cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-7.
24. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 1995;11:210-2.
25. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med 1995;1:686-92.
26. Zhou X, Suzuki H, Shimada Y, Imamura M, Yon J, Jiang H-Y, et al. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes Chromosomes Cancer 1995;13:285-90.
27. Suzuki H, Zhou X, Yin J, Lei J, Jiang H-Y, Suzuki Y, et al. Intragenic mutations of p15 and p16 in primary human esophageal cancers. Hum Mol Genet 1995;4:1883-8.
28. Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Mellasseau P, et al. The 1993-94 Généthon human genetic linkage map. Nat Genet (special number) 1994;7:246-9.
29. Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Isen O, et al. Reduction of homozygosity involving p53 in esophageal cancers demonstrated by polymerase chain reaction. Proc Natl Acad Sci USA 1991;88:4976-80.
30. Futreal PA, Barret JC, Wiseman RW. An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res 1991;19: 6977.
31. Jones MH, Sato T, Tangami A, Nakamura Y. Six microsatellite polymorphisms at candidate and confirmed tumor suppressor gene loci. Hum Mol Genet 1994;3:1991.
32. González MV, Pello MF, López-Larrea C, Suárez C, Menéndez MJ, Coto E. Loss of hoterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1995;1:1043-9.
33. Tamura G, Maesawa C, Suzuki Y, Tamada H, Satoh M, Ogasawara S, et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res 1994;54:1149-51.
34. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, et al. Mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-9.
35. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
36. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
37. Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc. Natl Acad Sci USA 1992;89:4452-6.
38. Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, et al. Barrett's esophagus: a model of human neoplastic progression. In: Cold Spring Harbour symposia on quantitative biology, vol 59. Cold Spring Harbour Laboratory Press, 1994:577-83.